About
Monoclonal Antibodies
Areas of Focus
Categories
Biologics & BiopharmaceuticalAntibody
Clinical Trials (10)
View allTotal Trials
10
As Lead Sponsor
9
As Collaborator
1
Total Enrollment
346
By Phase
PHASE1: 5PHASE2/PHASE3: 1PHASE2: 2PHASE1/PHASE2: 2
By Status
COMPLETED: 6RECRUITING: 2TERMINATED: 2
Clinical Trials Pipeline7 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details
Recent Trials
NCT06663839Lead Sponsor
A Study of NILK-2301 in Patients with Locally Advanced or Metastatic Low Tumor Volume (LTV) Colorectal Cancer
PHASE1Recruiting
25 participants
Started: Apr 12, 2024 · Completed: Jan 31, 2026
NCT05403554Lead Sponsor
A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers
PHASE1Recruiting
70 participants
Started: Apr 29, 2022 · Completed: Sep 30, 2026
NCT03985423Collaborator
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients With HLH
PHASE2/PHASE3Terminated
7 participants
Started: Jun 2, 2020 · Completed: Jun 29, 2021
NCT03241108Lead Sponsor
Study of an Anti-TLR4 mAb in Rheumatoid Arthritis
PHASE2Completed
90 participants
Started: May 10, 2017 · Completed: Jun 20, 2018
NCT01808469Lead Sponsor
First in Human Study of an Anti-Toll-like Receptor 4 (TLR4) Monoclonal Antibody (NI-0101) in Adult Healthy Volunteers
PHASE1Completed
80 participants
Started: Nov 30, 2012 · Completed: Mar 31, 2014
Locations (1)
Headquarters
Geneva, Switzerland
Map
Loading map...